Danish researchers analyzed data from over 77,000 adults using anti-obesity medications without diabetes. They found that 52 percent quit within 12 months. Eighteen percent stopped within three months, 31 percent by six months, and 42 percent by nine months.
Younger, Male, and Low-Income Patients Quit More
Adults under 30 quit 48 percent more than those aged 45 to 59. Residents of low-income areas stopped 14 percent more often than wealthier individuals. Men discontinued treatment more frequently than women. Researchers also noted that patients with chronic health conditions or prior psychiatric or gastrointestinal medications had higher dropout rates, likely due to side effects like nausea or vomiting.
GLP-1 Drugs Require Long-Term Use
Ozempic and Wegovy belong to GLP-1 receptor agonists, which mimic appetite-suppressing hormones to reduce weight. Stopping the medication often leads to weight regain. Professor Reimar W. Thomsen of Aarhus University said, “These drugs lose all appetite control benefits once patients stop taking them.” He emphasized that these medications work effectively only when taken consistently over time.
Costs Limit Access and Adherence
In Denmark, patients pay up to €313 for a month of Ozempic without diabetes coverage, compared to €120 in Germany. Researchers suggest high prices may prevent some people from maintaining treatment, particularly in low-income communities.
Implications for Public Health
Thomsen said the findings highlight the need to support patients who benefit from GLP-1 medications. Studies show these drugs reduce risks of heart disease, cancer, and addiction. With over half of European adults living with overweight or obesity, encouraging adherence remains essential. Researchers hope the study, presented at the European Association for the Study of Diabetes meeting in Vienna, will guide policies and programs to improve long-term outcomes and quality of life.
Supporting Patients Could Maximize Benefits
Thomsen urged targeted interventions to help patients continue therapy. Proper support could improve health outcomes, reduce disease risks, and enhance life quality. He stressed understanding who benefits most from GLP-1 drugs to design strategies that prevent early discontinuation.
